Shantha Biotechnics’ CEO on rebuilding vaccines business, products & strategy

By Jasleen Kaur Batra

  • 14 Oct 2014
Premium

Hyderabad-based vaccine maker Shantha Biotechnics was whacked four years ago after the World Health Organisation (WHO) cancelled its pre-qualified status and multi-million contract over quality issues of its flagship product Shan5. This came within a year of global pharma giant Sanofi acquiring majority stake in the company. The firm recently ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.